Vis enkel innførsel

dc.contributor.authorJi, Jianxiongen_US
dc.contributor.authorDing, Kaikaien_US
dc.contributor.authorLuo, Taoen_US
dc.contributor.authorXu, Ranen_US
dc.contributor.authorZhang, Xinen_US
dc.contributor.authorHuang, Binen_US
dc.contributor.authorChen, An-Jingen_US
dc.contributor.authorZhang, Dien_US
dc.contributor.authorMiletic, Hrvojeen_US
dc.contributor.authorBjerkvig, Rolfen_US
dc.contributor.authorThorsen, Fritsen_US
dc.contributor.authorWang, Jianen_US
dc.contributor.authorLi, Xingangen_US
dc.date.accessioned2020-08-07T12:22:36Z
dc.date.available2020-08-07T12:22:36Z
dc.date.issued2019
dc.PublishedJi J, Ding K, Luo T, Xu R, Zhang X, Huang B, Chen A, Zhang D, Miletic H, Bjerkvig R, Thorsen F, Wang J, Li X. PMEPA1 isoform a drives progression of glioblastoma by promoting protein degradation of the Hippo pathway kinase LATS1. Oncogene. 2019;39:1125–1139eng
dc.identifier.issn0950-9232
dc.identifier.issn1476-5594
dc.identifier.urihttps://hdl.handle.net/1956/23565
dc.description.abstractThe Hippo signaling pathway controls organ development and is also known, in cancer, to have a tumor suppressing role. Within the Hippo pathway, we here demonstrate, in human gliomas, a functional interaction of a transmembrane protein, prostate transmembrane protein, androgen induced 1 (PMEPA1) with large tumor suppressor kinase 1 (LATS1). We show that PMEPA1 is upregulated in primary human gliomas. The PMEPA1 isoform PMEPA1a was predominantly expressed in glioma specimens and cell lines, and ectopic expression of the protein promoted glioma growth and invasion in vitro and in an orthotopic xenograft model in nude mice. In co-immunoprecipitation experiments, PMEPA1a associated with the Hippo tumor suppressor kinase LATS1. This interaction led to a proteasomal degradation of LATS1 through recruitment of the ubiquitin ligase, neural precursor cell expressed, developmentally downregulated 4 (NEDD4), which led to silencing of Hippo signaling. Alanine substitution in PMEPA1a at PY motifs resulted in failed LATS1 degradation. Targeting of a downstream component in the Hippo signaling pathway, YAP, with shRNA, interfered with the growth promoting activities of PMEPA1a in vitro and in vivo. In conclusion, the presented work shows that PMEPA1a contributes to glioma progression by a dysregulation of the Hippo signaling pathway and thus represents a promising target for the treatment of gliomas.en_US
dc.language.isoengeng
dc.publisherSpringer Natureeng
dc.rightsAttribution CC BYeng
dc.rights.urihttp://creativecommons.org/licenses/by/4.0eng
dc.titlePMEPA1 isoform a drives progression of glioblastoma by promoting protein degradation of the Hippo pathway kinase LATS1en_US
dc.typePeer reviewed
dc.typeJournal article
dc.date.updated2020-01-28T09:54:28Z
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2019 The Author(s)
dc.identifier.doihttps://doi.org/10.1038/s41388-019-1050-9
dc.identifier.cristin1760052
dc.source.journalOncogene


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution CC BY
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution CC BY